Zydus Lifesciences Ltd (BOM:532321)
₹ 964.4 -8.55 (-0.88%) Market Cap: 970.41 Bil Enterprise Value: 965.67 Bil PE Ratio: 22.61 PB Ratio: 4.45 GF Score: 97/100

Q2 2025 Zydus Lifesciences Ltd Earnings Call Transcript

Nov 12, 2024 / 10:00AM GMT
Release Date Price: ₹950.1 (-1.90%)
Ganesh Nayak
Zydus Lifesciences Ltd - Executive Director

For today's call we have with us Dr. Sharvil P. Patel, managing director, Nitinkumar Parekh , Chief Financial Officer, Mr Arvind Bothra, head of investor relations and Mr Alo G from the managing director's office.

Let me now give you a broad overview of the developments during the quarter.

I'm happy to inform you that we delivered strong double digit growth during the quarter on the back of sustained growth across all our key businesses.

Our India branded formulations business continued to outgrow the market with 10% year on year growth driven by healthy volumes and contribution from new products.

The consumer wellness business continued to see robust demand in all categories.

The US formulations business continued its upward journey with a robust year on year growth driven by volume expansion and new products launched over the last 12 months, the international formulations business comprising of the emerging markets and Europe also delivered strong growth on the back of resilient demand across

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot